Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies

Episode Summary

Executive Summary: Jan Adair shares her journey from teen motherhood and welfare in Ohio to leading gene therapy translation and global access efforts. She describes how personal experience, scientific training, and work on first-in-human trials shaped her belief that breakthrough cell and gene therapies must become affordable, locally manufacturable, and globally inclusive.

Main Topics: From hardship to scientific ambition (Priority: 5/5): Adair traces how growing up in a Rust Belt family, becoming a teen mom, and relying on public assistance shaped her equity lens and motivation to make advanced medicines accessible. Education, resilience, and discovering science (Priority: 4/5): She explains her path through public schools, college with children, a chemistry/biochemistry degree, and the pressure-driven study style that helped her thrive academically. Doctoral and postdoctoral work in translational biology (Priority: 4/5): Her PhD focused on high-mobility group proteins and cancer biology, and her postdoc at NIEHS deepened her interest in preclinical and eventually clinical translation. First-in-human gene therapy trials at Fred Hutch (Priority: 5/5): Adair recounts leading IND development and phase 1 trials for ex vivo blood stem cell gene therapy, including a glioblastoma study that demonstrated feasibility and early clinical benefit. Global access, genomics, and equity in gene therapy (Priority: 5/5): She argues that African genomic diversity and global disease burden are underrepresented in reference genomes and therapy development, making inclusive research essential for worldwide impact. Gene therapy in a box and the limits of technical fixes (Priority: 4/5): Her automation efforts improved manufacturing workflows, but she learned that access barriers also involve local regulation, infrastructure, importing, and partnership with in-country stakeholders. Building the Global Gene Therapy Initiative (Priority: 5/5): Adair co-founded GGTI to create a continuous, virtual, worldwide learning network focused on pricing, manufacturing, regulation, and capacity-building for low- and middle-income countries.

Key Arguments: Personal experience with poverty and systems barriers gives scientists an essential equity perspective when designing therapies and access models. Pressurized, highly structured environments can help some people perform at their best, but access to opportunity—not merit alone—drives outcomes. Translation from basic science to patient care requires hands-on clinical trial experience, regulatory fluency, and multidisciplinary collaboration. First-in-human gene therapy can show meaningful biological activity and clinical benefit, but platform design and vector strategy must evolve with evidence. Global gene therapy access cannot be solved by a single technology; it requires local manufacturing, training, regulation, reimbursement strategy, and cultural trust. African genomic data and local participation must be central because therapies built primarily on European/male reference genomes risk poor global portability. Virtual, recurring knowledge-sharing through GGTI helps overcome visa, travel, and conference-access barriers for scientists and clinicians in lower-resource settings. Economic viability is now a second 'valley of death' for approved gene therapies, so cost reduction and localized delivery are as important as scientific innovation.

Data Points: Year of birth: 1977 - Adair says she was born in the Rust Belt downturn period in Northeast Ohio. Age at first pregnancy: 19 - She became pregnant while in college and already had a full academic scholarship. Children during college: 2 sons - Her first two children were born 16 months apart while she was still in college. Time to finish mother’s degree: 7 years - Her mother returned to college and completed a teaching degree slowly while raising a family. Time to complete undergraduate degree: 5 years - Adair finished college while parenting young children and working through pregnancy. Physics labs taken simultaneously: 3 - She took three physics labs in one term to fit childcare constraints. PhD duration: 4.5 years - She completed her PhD at Washington State University in a relatively short time. Children during PhD: 3 children - She had her third child during doctoral training and learned she was pregnant just before her final qualifying exam. Postdoc/clinical-translational work at Fred Hutch: 5 years - She spent about five years translating blood stem cell gene therapy into phase 1 trials. IND timeline: 6 months - Her first IND for the glioblastoma gene therapy trial cleared the FDA in about six months. First patient timing: 1 day after her one-year anniversary - The first patient on the trial was transplanted one day after her first year at Fred Hutch. Patients enrolled in initial trial sequence: 3 patients - The team enrolled three patients back to back, two weeks apart, to generate an early publication. Nine chemotherapy cycles: 9 cycles - The first glioblastoma patient could receive nine cycles of the chemo combination after modified MGMT gene transfer. Patient survival in one case: 6.5 years - Adair cites one patient who lived six and a half years after treatment, longer than expected prognosis. Global HIV burden: ~40 million people - She describes the mismatch between the scale of HIV burden and boutique gene-therapy development. Gene therapy product cost discussed: $13 million - She cites the price tag as a barrier for most African sickle cell patients seeking U.S. treatment. Point-of-care CAR-T cost in India: $35,107 per product - A Christian Medical College trial in Vellore reported local manufacturing costs, excluding some vector costs. Fogarty/NIH funding to Uganda: $1.27 million - She mentions a new grant to build training capacity in cell and gene therapy in Uganda.

Pivotal Quotes: "If I have a superpower, it's probably the ability to see networks of resources and figure out how to leverage them together." — Jan Adair: She reflects on how her background shaped her ability to connect people, institutions, and resources. "The pressure cooker was a feature, not a bug." — Jan Adair: She describes how rigid timelines and intense expectations helped her thrive academically and professionally. "This is a celebration of what is possible. It is also a very, very sharp punch to the gut about our failure in not proceeding with the benefit of health all in mind." — Jan Adair: She reacts to personalized gene therapy milestones while emphasizing the inequity of global access.

Implications: The episode argues that gene therapy’s next frontier is not only scientific efficacy, but equitable delivery: local manufacturing, global genomics, fair pricing, and trust-building with communities outside wealthy countries.